The federal Food and Drug Administration (FDA) will conduct a joint meeting of its Reproductive Health Drugs Advisory Committee and its Drug Safety and Risk Management Advisory Committee on December 8. The committees will discuss Yaz, Yasmin and other drospirenone-based birth control pills.
The meeting comes after a federally funded study revealed that women who take Yaz and Yasmin have a 150 percent increased risk of blood clots when compared to users of other birth control pills. Despite the alarming results, the FDA could not reach a conclusion on the risks and benefits of Yaz and Yasmin, so it will discuss the issue further on December 8.
The two committees will examine the study’s results and make a joint recommendation to the FDA about what it can do to protect women from blood clots associated with the birth control pills. The FDA is under no obligation to follow the committees’ advice, but it has a history of making its decisions based on committee recommendations.
The meeting takes place in the midst of the thousands of pending lawsuits against Bayer for injuries and deaths linked to Yaz and Yasmin.
If you are Yaz or Yasminuser, have you experienced any health complications?
Harrell & Nowak, L.L.C. – New Orleans injury lawyers